


Searching News Database: seizures
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 17 May 2023
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
HSMN NewsFeed - 15 Feb 2023
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
HSMN NewsFeed - 6 Jan 2023
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
HSMN NewsFeed - 24 Aug 2022
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
HSMN NewsFeed - 8 Nov 2021
Azurity Pharmaceuticals, Inc. Announces FDA Approval of Eprontia(TM) (Topiramate) Oral Solution
Azurity Pharmaceuticals, Inc. Announces FDA Approval of Eprontia(TM) (Topiramate) Oral Solution
HSMN NewsFeed - 1 Jun 2020
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
HSMN NewsFeed - 28 Jan 2020
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
HSMN NewsFeed - 27 Sep 2019
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
HSMN NewsFeed - 29 Jul 2019
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
HSMN NewsFeed - 16 Apr 2019
Cerebral Therapeutics Strengthens Clinical Development Leadership with Strategic Appointments
Cerebral Therapeutics Strengthens Clinical Development Leadership with Strategic Appointments
HSMN NewsFeed - 18 Mar 2019
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
HSMN NewsFeed - 3 Dec 2018
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
HSMN NewsFeed - 30 Aug 2018
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
HSMN NewsFeed - 17 Aug 2018
FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder
FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder
HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
HSMN NewsFeed - 29 May 2018
Zeto Announces First Dry Electrode, Wireless EEG Headset Approved by FDA for Clinical Use
Zeto Announces First Dry Electrode, Wireless EEG Headset Approved by FDA for Clinical Use
HSMN NewsFeed - 20 Apr 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 27 Jan 2017
Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing
Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing
HSMN NewsFeed - 3 Jan 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
HSMN NewsFeed - 22 Mar 2016
First FDA-Approved Medicine Manufactured Using 3D Printing Technology Now Available
First FDA-Approved Medicine Manufactured Using 3D Printing Technology Now Available
HSMN NewsFeed - 24 Feb 2016
Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE(R) (loxapine) inhalation powder
Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE(R) (loxapine) inhalation powder
HSMN NewsFeed - 15 Jan 2016
Impax Receives Approval of EMVERM(TM) (mebendazole) Chewable Tablets, 100 mg
Impax Receives Approval of EMVERM(TM) (mebendazole) Chewable Tablets, 100 mg
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 1 Oct 2015
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
HSMN NewsFeed - 19 Aug 2014
FDA Approves Use of AFLURIA(R) Influenza Vaccine with PharmaJet’s Needle-Free Injector
FDA Approves Use of AFLURIA(R) Influenza Vaccine with PharmaJet’s Needle-Free Injector
HSMN NewsFeed - 20 Feb 2014
Cyberonics Announces CE Mark Approval Of The AspireSR(TM) Generator For VNS Therapy(R)
Cyberonics Announces CE Mark Approval Of The AspireSR(TM) Generator For VNS Therapy(R)
HSMN NewsFeed - 3 Jan 2014
NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara(R) in Europe
NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara(R) in Europe
HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
HSMN NewsFeed - 15 Nov 2013
Wright Medical Group, Inc. Completes Acquisition of Biotech International
Wright Medical Group, Inc. Completes Acquisition of Biotech International
HSMN NewsFeed - 16 Oct 2013
Wright Medical Group, Inc. Announces Definitive Agreement to Acquire Biotech International
Wright Medical Group, Inc. Announces Definitive Agreement to Acquire Biotech International
HSMN NewsFeed - 21 Aug 2013
Novo Nordisk receives U.S. FDA clearance for the insulin injection device NovoPen Echo(R)
Novo Nordisk receives U.S. FDA clearance for the insulin injection device NovoPen Echo(R)
HSMN NewsFeed - 19 Aug 2013
Supernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR(TM)
Supernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR(TM)
HSMN NewsFeed - 26 Jul 2013
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
HSMN NewsFeed - 5 Jun 2013
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
HSMN NewsFeed - 1 Mar 2013
Wright Medical Group, Inc. Completes Acquisition of BioMimetic Therapeutics, Inc.
Wright Medical Group, Inc. Completes Acquisition of BioMimetic Therapeutics, Inc.
HSMN NewsFeed - 26 Feb 2013
FDA Advisory Panel Recommends Approval of the NeuroPace RNS(R) System for Medically Refractory Epilepsy
FDA Advisory Panel Recommends Approval of the NeuroPace RNS(R) System for Medically Refractory Epilepsy
HSMN NewsFeed - 21 Feb 2013
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
HSMN NewsFeed - 19 Nov 2012
Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into Agreement to Combine Businesses
Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into Agreement to Combine Businesses
HSMN NewsFeed - 2 Apr 2012
UCLA Neurologist and Innovator of Trigeminal Nerve Stimulation Joins NeuroSigma
UCLA Neurologist and Innovator of Trigeminal Nerve Stimulation Joins NeuroSigma
HSMN NewsFeed - 15 Mar 2012
Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients
Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients
HSMN NewsFeed - 19 Sep 2011
Wright Medical Group, Inc. Names Robert J. Palmisano President and Chief Executive Officer
Wright Medical Group, Inc. Names Robert J. Palmisano President and Chief Executive Officer
HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
HSMN NewsFeed - 14 Jun 2011
CerebralRx Enters Global Neuromodulation Market With the FitNeS(TM) System for Treating Epilepsy
CerebralRx Enters Global Neuromodulation Market With the FitNeS(TM) System for Treating Epilepsy
HSMN NewsFeed - 13 Jun 2011
Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga (ezogabine)
Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga (ezogabine)
HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
HSMN NewsFeed - 16 Sep 2010
Medtronic Receives European CE Mark Approval for Deep Brain Stimulation Therapy for Refractory Epilepsy
Medtronic Receives European CE Mark Approval for Deep Brain Stimulation Therapy for Refractory Epilepsy
HSMN NewsFeed - 8 Jun 2010
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
HSMN NewsFeed - 7 Jun 2010
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
Elekta Introduces Next Generation MEG System for Monitoring the Brain in Action
HSMN NewsFeed - 30 Mar 2010
Philips Launches New Endovascular Therapeutic Hypothermia System To Help Enhance Patient Care
Philips Launches New Endovascular Therapeutic Hypothermia System To Help Enhance Patient Care
HSMN NewsFeed - 3 Feb 2010
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
HSMN NewsFeed - 7 Dec 2009
Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy
Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy
HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
HSMN NewsFeed - 10 Sep 2009
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
HSMN NewsFeed - 25 Aug 2009
CAS Medical Systems, Inc. Announces FDA 510(k) Clearance Expanding Labeling for FORE-SIGHT Cerebral Oximeter
CAS Medical Systems, Inc. Announces FDA 510(k) Clearance Expanding Labeling for FORE-SIGHT Cerebral Oximeter
HSMN NewsFeed - 29 Jul 2009
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
HSMN NewsFeed - 1 Jun 2009
FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
HSMN NewsFeed - 11 May 2009
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
HSMN NewsFeed - 7 May 2009
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
HSMN NewsFeed - 17 Apr 2009
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network
HSMN NewsFeed - 2 Apr 2009
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
HSMN NewsFeed - 27 Mar 2009
Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
HSMN NewsFeed - 18 Dec 2008
StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SC® Cells In A Myelin Disease
StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SC® Cells In A Myelin Disease
HSMN NewsFeed - 16 Dec 2008
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
HSMN NewsFeed - 17 Oct 2008
Valeant Pharmaceuticals and GlaxoSmithKline Complete Worldwide Collaboration Agreement for Retigabine
Valeant Pharmaceuticals and GlaxoSmithKline Complete Worldwide Collaboration Agreement for Retigabine
HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
HSMN NewsFeed - 25 Sep 2008
UCB Withdraws EU Marketing Authorisation Application for Lacosamide in Diabetic Neuropathic Pain
UCB Withdraws EU Marketing Authorisation Application for Lacosamide in Diabetic Neuropathic Pain
HSMN NewsFeed - 24 Sep 2008
New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 24 Jul 2008
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
HSMN NewsFeed - 16 Jul 2008
Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
HSMN NewsFeed - 2 Jul 2008
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
HSMN NewsFeed - 17 Jun 2008
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
HSMN NewsFeed - 5 Jun 2008
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 29 May 2008
StemCells Confirms Previously Reported Batten Trial Death Was Due to Natural Progression of Disease
StemCells Confirms Previously Reported Batten Trial Death Was Due to Natural Progression of Disease
HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
HSMN NewsFeed - 8 May 2008
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
HSMN NewsFeed - 22 Apr 2008
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
HSMN NewsFeed - 16 Apr 2008
Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression
Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression
HSMN NewsFeed - 19 Mar 2008
Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL
Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL
HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
HSMN NewsFeed - 11 Dec 2007
Cyberkinetics Receives FDA Response Letter on Andara(TM) OFS(TM) System for Acute Spinal Cord Injury
Cyberkinetics Receives FDA Response Letter on Andara(TM) OFS(TM) System for Acute Spinal Cord Injury
HSMN NewsFeed - 29 Nov 2007
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
HSMN NewsFeed - 27 Nov 2007
Valeant Pharmaceuticals Completes Enrollment of Second Pivotal Phase 3 Trial for Epilepsy Drug Retigabine
Valeant Pharmaceuticals Completes Enrollment of Second Pivotal Phase 3 Trial for Epilepsy Drug Retigabine
HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 12 Nov 2007
Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
HSMN NewsFeed - 17 Aug 2007
UCB Announces Submission of Lacosamide Marketing Application for Diabetic Neuropathic Pain
UCB Announces Submission of Lacosamide Marketing Application for Diabetic Neuropathic Pain
HSMN NewsFeed - 6 Aug 2007
Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP
Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP
HSMN NewsFeed - 24 Jul 2007
Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
HSMN NewsFeed - 3 Jul 2007
Azur Pharma Announces the Acquisition of FazaClo for $42 Million Plus Contingent Milestones
Azur Pharma Announces the Acquisition of FazaClo for $42 Million Plus Contingent Milestones
HSMN NewsFeed - 2 Jul 2007
Valeant Pharmaceuticals Settles Suit with Kali Laboratories on Diastat Generic Challenge
Valeant Pharmaceuticals Settles Suit with Kali Laboratories on Diastat Generic Challenge
HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
HSMN NewsFeed - 22 Jun 2007
FDA Approves Carnitor(R) SF (Levocarnitine) Sugar-Free Oral Solution For Patients With Carnitine Deficiency
FDA Approves Carnitor(R) SF (Levocarnitine) Sugar-Free Oral Solution For Patients With Carnitine Deficiency
HSMN NewsFeed - 21 Jun 2007
Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review
Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review
HSMN NewsFeed - 18 Jun 2007
StemCells, Inc. Announces Important Milestone in Batten Disease Clinical Trial
StemCells, Inc. Announces Important Milestone in Batten Disease Clinical Trial
HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
HSMN NewsFeed - 31 May 2007
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
HSMN NewsFeed - 24 May 2007
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
HSMN NewsFeed - 14 May 2007
Questcor Receives FDA Action Letter for H.P. Acthar(R) Gel for Treatment of Infantile Spasms
Questcor Receives FDA Action Letter for H.P. Acthar(R) Gel for Treatment of Infantile Spasms
HSMN NewsFeed - 1 May 2007
New Data Shows Once a Day Lamictal(R) XR(TM) Is Effective in Treating Patients With Partial Seizures
New Data Shows Once a Day Lamictal(R) XR(TM) Is Effective in Treating Patients With Partial Seizures
HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 24 Apr 2007
Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease
Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease
HSMN NewsFeed - 19 Apr 2007
Abraxis BioScience Receives FDA Tentative Approval for Fosphenytoin Sodium Injection, USP
Abraxis BioScience Receives FDA Tentative Approval for Fosphenytoin Sodium Injection, USP
HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
HSMN NewsFeed - 10 Apr 2007
Amarin Appoints Declan Doogan to New Position of President-Research and Development
Amarin Appoints Declan Doogan to New Position of President-Research and Development
HSMN NewsFeed - 3 Apr 2007
Amarin Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations
Amarin Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations
HSMN NewsFeed - 20 Mar 2007
Keppra(R) Approved for US Epilepsy Patients with One of the Most Debilitating Seizure Types
Keppra(R) Approved for US Epilepsy Patients with One of the Most Debilitating Seizure Types
HSMN NewsFeed - 19 Mar 2007
Transoma Medical Closes $13 Million in Series C Funding to Launch Implantable Wireless Monitoring Devices
Transoma Medical Closes $13 Million in Series C Funding to Launch Implantable Wireless Monitoring Devices
HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
HSMN NewsFeed - 30 Jan 2007
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
HSMN NewsFeed - 25 Jan 2007
Valeant Pharmaceuticals Developing Intranasal Diazepam for the At-Home Treatment of Emergency Seizures
Valeant Pharmaceuticals Developing Intranasal Diazepam for the At-Home Treatment of Emergency Seizures
HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
HSMN NewsFeed - 18 Dec 2006
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
HSMN NewsFeed - 15 Dec 2006
Caraco Pharmaceutical Laboratories Ltd. to Market Extended Phenytoin Sodium Capsules, USP 100mg
Caraco Pharmaceutical Laboratories Ltd. to Market Extended Phenytoin Sodium Capsules, USP 100mg
HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
HSMN NewsFeed - 8 Sep 2006
Taro Announces Filing Of ANDA For Oxcarbazepine Tablets 150, 300 And 600 MG
Taro Announces Filing Of ANDA For Oxcarbazepine Tablets 150, 300 And 600 MG
HSMN NewsFeed - 18 Jul 2006
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
HSMN NewsFeed - 26 Jun 2006
Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder
Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder
HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
HSMN NewsFeed - 23 May 2006
AVANIR Announces the Intended Acquisition of a Private Specialty Pharmaceutical Company
AVANIR Announces the Intended Acquisition of a Private Specialty Pharmaceutical Company
HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
Additional items found! 287
Members Archive contains
287 additional stories matching:
seizures
(Password required)
seizures
(Password required)
